Raymond James downgrades Doximity stock rating on weak growth outlook

Raymond James downgraded Doximity to Outperform from Strong Buy and cut its price target to $23 from $40 after the company issued fiscal 2027 growth guidance of 4%, well below Street expectations of 8%. The firm sees continued headwinds through fiscal 2027, limited share gains, and a longer path to re-rating even with AI monetization as a future growth driver. Doximity also reported Q4 fiscal 2026 revenue of $145.4 million, up 5.1% year over year and slightly above estimates, but softer guidance and multiple analyst downgrades point to near-term pressure.

Analysis

The key issue is not the current print, but the reset in the platform's terminal growth narrative. A move from “AI optionality” to “AI as a delayed monetization vector” typically compresses multiple twice: first on revenue growth expectations, then again on the duration of the re-acceleration gap. That makes DOCS vulnerable to a prolonged de-rating regime even if downside in near-term estimates stabilizes.

Second-order, the downgrade cycle matters because this is now a crowded “show me” story: multiple research shops are converging on the same concern that product investment is outrunning monetization. That usually pressures incremental buyers to wait for proof, which can create a self-reinforcing air pocket in the stock as active managers de-risk ahead of the next guide. The market is effectively being asked to underwrite 12-18 months of muted acceleration before any AI contribution becomes visible.

The contrarian case is that expectations may already be resetting faster than fundamentals are deteriorating. If the company can merely sustain low-single-digit top-line growth while holding margins and demonstrating early search/AI attach, the stock can rally on “less bad” rather than true acceleration. But that would likely require at least one or two clean quarters of stable revisions first; until then, every print is more likely to be sold than bought.

The broader beneficiary set is the competitive layer around healthcare workflow and provider attention: AI-native point solutions, ad-tech adjacent peers, and any company able to monetize clinician traffic faster than DOCS. If DOCS is forced to spend more on product and distribution to defend share, its free-cash-flow story becomes more back-half weighted, which reduces near-term valuation support and increases the odds of further estimate cuts.

Key Decisions for Investors

• Short DOCS on rallies toward the low-$20s with a 1-3 month horizon; risk/reward favors downside to the high teens if the market continues to price in delayed AI monetization and additional estimate cuts.
• Pair trade: short DOCS / long a profitable AI-enabled workflow beneficiary in adjacent software or healthcare IT over the next 2-4 quarters; the trade captures multiple compression in the delayed-monetization name while retaining upside to AI adoption elsewhere.
• Buy DOCS put spreads 2-4 months out only if shares rebound on a “not as bad as feared” reaction; structure for a mean-reversion lower as revisions continue to drift down.
• If already long, trim into any post-earnings bounce and wait for evidence of two consecutive quarters of stable guidance before re-entering; the risk is not bankruptcy, it is a long valuation reset.
• Watch for a catalyst above all: any signal that AI/search revenue is becoming material within 1-2 quarters would invalidate the bear case, but absent that, maintain a defensive stance.